GHRL and neoplasm: We therefore believe that unacylated ghrelin is a prototypic 3D-specific breast cancer cell therapeutic and that characterizing its mechanism of action in a biologically relevant ECM will lead to a better understanding of how the tumor microenvironment affects response to therapy.